AMENDMENTS TO THE CLAIMS

Please amend the claims as follows. Cancel Claims 1-22 without prejudice and insert therefore new Claims 21-32. This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-22 (Canceled)

23. (New) A compound of the Formula I:



I

wherein:

A is thiazolyl, which is optionally substituted with one to five substituents that are independently selected from the group consisting of: halogen, –CN, NO_2, -C_{1-6}alkyl, -C_{1-6}alkenyl, -C_{1-6}alkynyl,–OR^1, –NR^1R^2, –$C(=NR^1)NR^2R^3$, –$N(=NR^1)NR^2R^3$, –NR^1COR^2, -$NR^1CO_2R^2$, -$NR^1SO_2R^4$, –$NR^1CONR^2R^3$,–SR^4, -SOR^4, –SO_2R^4, –$SO_2NR^1R^2$, -COR^1, -CO_2R^1, –$CONR^1R^2$, -$C(=NR^1)R^2$, or –$C(=NOR^1)R^2$ substituents; wherein the alkyl, alkenyl or alkynyl may optionally be substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –$O(C_{0-6}$alkyl), –$O(C_{3-7}$cycloalkyl), –O(aryl), –$N(C_{0-6}$alkyl)$(C_{0-6}$alkyl), -$N(C_{0-6}$alkyl)$(C_{3-7}$cycloalkyl), –$N(C_{0-6}$alkyl)(aryl) substituents;

B is pyridyl, which is optionally substituted with one to five substituents that are independently selected from the group consisting of: halogen, –CN, NO_2, -C_{1-6}alkyl, -C_{1-6}alkenyl, -C_{1-6}alkynyl, -OR^5, –NR^5R^6, -$C(=NR^5)NR^6R^7$, -$N(=NR^5)NR^6R^7$, –NR^5COR^6, -$NR^5CO_2R^6$, -$NR^5SO_2R^8$, –$NR^5CONR^6R^7$,–SR^8, -SOR^8, –SO_2R^8, –$SO_2NR^5R^6$, -COR^5, -CO_2R^5, –$CONR^5R^6$, -$C(=NR^5)R^6$,–$C(=NOR^5)R^6$, or aryl substituents; wherein the alkyl, alkenyl or alkynyl may optionally be substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –O(C_{0-6}alkyl), –O(C_{3-7}cycloalkyl), –O(aryl), –N(C_{0-6}alkyl)(C_{0-6}alkyl), -N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), –N(C_{0-6}alkyl)(aryl) substituents;

R^1, R^2, and R^3 each independently is –C_{0-6}alkyl, –C_{3-7}cycloalkyl, or aryl; any of which is optionally substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –O(C_{0-6}alkyl), –O(C_{3-7}cycloalkyl), –O(aryl), –N(C_{0-6}alkyl)(C_{0-6}alkyl), -N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), –N(C_{0-6}alkyl)(aryl) substituents;

R^4 is –C_{1-6}alkyl, –C_{3-7}cycloalkyl, or aryl; which is optionally substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –O(C_{0-6}alkyl), –O(C_{3-7}cycloalkyl), -O(aryl), –N(C_{0-6}alkyl)(C_{0-6}alkyl), –N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), –N(C_{0-6}alkyl)(aryl) substituents;

R^5, R^6, and R^7 each independently is –C_{0-6}alkyl, –C_{3-7}cycloalkyl, or aryl; any of which is optionally substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –O(C_{0-6}alkyl), –O(C_{3-7}cycloalkyl), –O(aryl), –N(C_{0-6}alkyl)(C_{0-6}alkyl), -N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), –N(C_{0-6}alkyl)(aryl) substituents;

R^8 is –C_{1-6}alkyl, –C_{3-7}cycloalkyl, or aryl; which is optionally substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –O(C_{0-6}alkyl), –O(C_{3-7}cycloalkyl), -O(aryl), –N(C_{0-6}alkyl)(C_{0-6}alkyl), –N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), –N(C_{0-6}alkyl)(aryl) substituents;

wherein the compound is isotopically labeled with at least one ^{11}C, ^{13}C, ^{14}C, ^{18}F, ^{15}O, ^{13}N, ^{35}S, ^{2}H, or ^{3}H atom;
or a pharmaceutically acceptable salt thereof.

24. (New) The compound of Claim 23 wherein:

A is thiazolyl, which is optionally substituted with one to five substituents that are independently selected from the group consisting of: halogen, –CN, NO_2, -C_{1-6}alkyl, -C_{1-6}alkenyl, -C_{1-6}alkynyl, –OR^1, –NR^1R^2, –$C(=NR^1)NR^2R^3$, –$N(=NR^1)NR^2R^3$, –NR^1COR^2, -$NR^1CO_2R^2$, -$NR^1SO_2R^4$, –$NR^1CONR^2R^3$,–SR^4, -SOR^4, –SO_2R^4, –$SO_2NR^1R^2$, -COR^1, -CO_2R^1, –$CONR^1R^2$, -$C(=NR^1)R^2$, or –$C(=NOR^1)R^2$ substituents;

B is pyridyl, which is optionally substituted with one to five substituents that are independently selected from the group consisting of: halogen, –CN, NO_2, -C_{1-6}alkyl, -C_{1-6}alkenyl, -C_{1-6}alkynyl, -OR^5, –NR^5R^6, -$C(=NR^5)NR^6R^7$, -$N(=NR^5)NR^6R^7$, –NR^5COR^6, -$NR^5CO_2R^6$, -$NR^5SO_2R^8$, –$NR^5CONR^6R^7$,–SR^8, -SOR^8, –SO_2R^8, –$SO_2NR^5R^6$, -COR^5, -CO_2R^5, –$CONR^5R^6$, -$C(=NR^5)R^6$,–$C(=NOR^5)R^6$, or aryl substituents;

R^1, R^2, and R^3 each independently is –C_{0-6}alkyl, –C_{3-7}cycloalkyl, or aryl; any of which is optionally substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –O(C_{0-6}alkyl), –O(C_{3-7}cycloalkyl), –O(aryl), –N(C_{0-6}alkyl)(C_{0-6}alkyl), -N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), –N(C_{0-6}alkyl)(aryl) substituents;

R^4 is –C_{1-6}alkyl, –C_{3-7}cycloalkyl, or aryl; optionally substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –O(C_{0-6}alkyl), –O(C_{3-7}cycloalkyl), -O(aryl), –N(C_{0-6}alkyl)(C_{0-6}alkyl), –N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), –N(C_{0-6}alkyl)(aryl) substituents;

R^5, R^6, and R^7 each independently is –C_{0-6}alkyl, –C_{3-7}cycloalkyl, or aryl; any of which is optionally substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –O(C_{0-6}alkyl), –O(C_{3-7}cycloalkyl), –O(aryl), –N(C_{0-6}alkyl)(C_{0-6}alkyl), -N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), –N(C_{0-6}alkyl)(aryl) substituents;

R^8 is –C_{1-6}alkyl, –C_{3-7}cycloalkyl, or aryl; optionally substituted with 1-5 substituents that are independently selected from the group consisting of: halogen, –CN, –C_{1-6}alkyl, –O(C_{0-6}alkyl), –O(C_{3-7}cycloalkyl), -O(aryl), –N(C_{0-6}alkyl)(C_{0-6}alkyl), –N(C_{0-6}alkyl)(C_{3-7}cycloalkyl), –N(C_{0-6}alkyl)(aryl) substituents or a pharmaceutically acceptable salt thereof; and

wherein the compound is isotopically labeled with at least one ^{11}C, ^{13}C, ^{14}C, ^{18}F, ^{15}O, ^{13}N, ^{35}S, ^{2}H, or ^{3}H atom;

and except when A = 6-methyl-2-pyridyl then B cannot be 3-methoxyphenyl or unsubstituted phenyl.

25. (New) The compound of Claim 23 wherein:

A is thiazolyl, which is optionally substituted with one to three substituents that are independently selected from the group consisting of: halogen, –CN, NO_2, -C_{1-6}alkyl, -C_{1-6}alkenyl, -C_{1-6}alkynyl, –OR^1, –NR^1R^2, –$C(=NR^1)NR^2R^3$, –$N(=NR^1)NR^2R^3$, –NR^1COR^2, -$NR^1CO_2R^2$, -$NR^1SO_2R^4$, –$NR^1CONR^2R^3$,–SR^4, -SOR^4, –SO_2R^4, –$SO_2NR^1R^2$, -COR^1, -CO_2R^1, –$CONR^1R^2$, -$C(=NR^1)R^2$, or –$C(=NOR^1)R^2$ substituents; and

B is pyridyl, which is optionally substituted with one to three substituents that are independently selected from the group consisting of: halogen, –CN, NO_2, -C_{1-6}alkyl, -C_{1-6}alkenyl, -C_{1-6}alkynyl, -OR^5, –NR^5R^6, -$C(=NR^5)NR^6R^7$, -$N(=NR^5)NR^6R^7$, –NR^5COR^6, -$NR^5CO_2R^6$, -$NR^5SO_2R^8$, –$NR^5CONR^6R^7$,–SR^8, -SOR^8, –SO_2R^8, –$SO_2NR^5R^6$, -COR^5, -CO_2R^5, –$CONR^5R^6$, -$C(=NR^5)R^6$,–$C(=NOR^5)R^6$, aryl or substituents;

wherein the compound is isotopically labeled with at least one ^{11}C, ^{13}C, ^{14}C, ^{18}F, ^{15}O, ^{13}N, ^{35}S, ^{2}H, or ^{3}H atom;

or a pharmaceutically acceptable salt thereof.

26. (New) The compound of Claim 23 wherein A is thiazolyl, which is optionally substituted with one to five substituents that are independently selected from the group consisting of: halogen, -C_{0-6}alkyl, -N(C_{0-6}alkyl) (C_{0-6}alkyl), or –O(C_{0-6}alkyl) substituents.

27. (New) The compound of Claim 26 wherein A is thiazolyl, which is optionally substituted with one to two substituents that are independently selected from the group consisting of: halogen, -C_{1-2}alkyl, or –O(C_{1-3}alkyl) substituents.

28. (New) The compound of Claim 23 wherein B is pyridyl, which is optionally substituted with one to five substituents that are independently selected from the group consisting of: halogen, -C_{0-6}alkyl, -N(C_{0-6}alkyl) (C_{0-6}alkyl), or –O(C_{0-16}alkyl) substituents.

29. (New) The compound of Claim 28 wherein B is pyridyl, which is optionally substituted with one to two substituents that are independently selected from the group consisting of: halogen, -C_{1-2}alkyl, or –O(C_{1-3}alkyl) substituents.

30. (New) A compound which is selected from the group consisting of:


,


,


,


,


,


,


,


,


,


,



,



,



,



,



,



,

or a pharmaceutically acceptable salt thereof.

31. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 23 or a pharmaceutically acceptable salt thereof.

32. (New) A pharmaceutical composition which comprises an inert carrier and the compound of Claim 30 or a pharmaceutically acceptable salt thereof.